Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
0.6794 +0.0262 (+4.01%) 04/17/25 [NASDAQ]
0.6750 x 2,000 0.6780 x 1,000
Realtime by (Cboe BZX)
0.6750 x 2,000 0.6780 x 1,000
Realtime 0.6750 -0.0044 (-) 04/17/25
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.6500
Day High
0.6899
Open 0.6500
Previous Close 0.6532 0.6532
Volume 3,490,700 3,490,700
Avg Vol 4,280,725 4,280,725
Stochastic %K 48.96% 48.96%
Weighted Alpha -54.56 -54.56
5-Day Change +0.0094 (+1.40%) +0.0094 (+1.40%)
52-Week Range 0.5150 - 2.0600 0.5150 - 2.0600
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 198,394
  • Shares Outstanding, K 292,014
  • Annual Sales, $ 4,060 K
  • Annual Income, $ -54,050 K
  • EBIT $ -55 M
  • EBITDA $ -53 M
  • 60-Month Beta 3.78
  • Price/Sales 47.04
  • Price/Cash Flow N/A
  • Price/Book 6.42
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.19
  • Most Recent Earnings $-0.05 on 03/05/25
  • Next Earnings Date 05/13/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 224.09% ( +19.37%)
  • Historical Volatility 113.71%
  • IV Percentile 98%
  • IV Rank 76.99%
  • IV High 268.16% on 04/02/25
  • IV Low 76.66% on 08/08/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 2,459
  • Volume Avg (30-Day) 538
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 37,557
  • Open Int (30-Day) 35,943

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.07
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5150 +31.92%
on 03/19/25
Period Open: 0.5726
0.8000 -15.07%
on 03/28/25
+0.1068 (+18.65%)
since 03/17/25
3-Month
0.5150 +31.92%
on 03/19/25
Period Open: 0.7100
0.8199 -17.14%
on 01/24/25
-0.0306 (-4.31%)
since 01/17/25
52-Week
0.5150 +31.92%
on 03/19/25
Period Open: 1.4400
2.0600 -67.02%
on 05/16/24
-0.7606 (-52.82%)
since 04/17/24

Most Recent Stories

More News
Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

OCGN : 0.6794 (+4.01%)
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

OCGN : 0.6794 (+4.01%)
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates

Watchers on Stocktwits expressed optimism about the company’s pipeline and its aim to secure three BLAs over the next three years.

VHT : 246.13 (-0.42%)
VTI : 258.75 (+0.21%)
IWM : 186.48 (+0.82%)
OCGN : 0.6794 (+4.01%)
Ocugen (OCGN) Q4 2024 Earnings Call Transcript

OCGN earnings call for the period ending December 31, 2024.

OCGN : 0.6794 (+4.01%)
Ocugen: Q4 Earnings Snapshot

Ocugen: Q4 Earnings Snapshot

OCGN : 0.6794 (+4.01%)
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

OCGN : 0.6794 (+4.01%)
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

OCGN : 0.6794 (+4.01%)
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

OCGN : 0.6794 (+4.01%)
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

OCGN : 0.6794 (+4.01%)
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

OCGN : 0.6794 (+4.01%)

Business Summary

Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 0.7361
2nd Resistance Point 0.7130
1st Resistance Point 0.6962
Last Price 0.6794
1st Support Level 0.6563
2nd Support Level 0.6332
3rd Support Level 0.6164

See More

52-Week High 2.0600
Fibonacci 61.8% 1.4698
Fibonacci 50% 1.2875
Fibonacci 38.2% 1.1052
Last Price 0.6794
52-Week Low 0.5150

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro